Active Ingredient History

  • Now
Casopitant (INN), former tentative trade names Rezonic (U.S.) and Zunrisa (Europe), is an NK1 receptor antagonist which was undergoing research for the treatment of chemotherapy-induced nausea and vomiting. It was under development by GlaxoSmithKline. In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn and development was discontinued in September 2009 because GlaxoSmithKline decided that further safety assessment was necessary. However, a 2022 review listed casopitant as under development as a potential novel antidepressant for the treatment of major depressive disorder, with a phase 2 clinical trial having been completed.   Wikipedia

  • SMILES: C[C@@H](N(C)C(=O)N1CC[C@@H](C[C@@H]1c2ccc(F)cc2C)N3CCN(CC3)C(=O)C)c4cc(cc(c4)C(F)(F)F)C(F)(F)F
  • Mol. Mass: 616.62
  • ALogP: 6.65
  • ChEMBL Molecules:
More Chemistry
casopitant | casopitant mesilate | casopitant mesylate | gw679769 | gw-679769 | zunrisa


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue